Cetera Investment Advisers Buys 27,765 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Cetera Investment Advisers lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 83.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,868 shares of the company’s stock after buying an additional 27,765 shares during the quarter. Cetera Investment Advisers’ holdings in Teva Pharmaceutical Industries were worth $989,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in TEVA. Sequoia Financial Advisors LLC raised its stake in shares of Teva Pharmaceutical Industries by 0.7% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 111,575 shares of the company’s stock worth $1,813,000 after purchasing an additional 826 shares in the last quarter. Edmond DE Rothschild Holding S.A. grew its position in Teva Pharmaceutical Industries by 4.0% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock valued at $346,000 after acquiring an additional 947 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in Teva Pharmaceutical Industries by 9.6% in the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after acquiring an additional 1,180 shares during the last quarter. QRG Capital Management Inc. grew its position in Teva Pharmaceutical Industries by 0.8% in the second quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock valued at $2,355,000 after acquiring an additional 1,191 shares during the last quarter. Finally, United Services Automobile Association grew its holdings in shares of Teva Pharmaceutical Industries by 3.1% during the second quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock worth $669,000 after purchasing an additional 1,249 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TEVA. Jefferies Financial Group lifted their price objective on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. Finally, Barclays upped their price objective on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.89.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $17.96 on Friday. The firm has a market cap of $20.35 billion, a PE ratio of -46.05, a P/E/G ratio of 1.20 and a beta of 0.88. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The stock has a fifty day moving average price of $17.95 and a 200-day moving average price of $16.59. Teva Pharmaceutical Industries Limited has a 12 month low of $8.06 and a 12 month high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The company had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. Equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.